NR4A1 and breast cancer: PAM50-based Prosigna ROR derived risk-groups reported adjusted HRs of 2.15 for distant recurrence (95% CI: 1.21–3.81, p = 0.009) between intermediate- vs. low-risk groups and of 4.26 (95% CI: 2.44–7.43, p < 0.0001) for high- vs. low-risk groups in the postmenopausal hormonal receptor-positive early breast cancer patients derived from the ABCSG-8 trial [4].